Conversely, CASZ1 is downregulated in hepatocellular carcinoma, colorectal cancer, esophageal cancer, lung adenocarcinoma, and clear cell renal cell carcinoma, and its decreased expression is linked to patient prognosis, with this diminished expression serving as a potential prognostic indicator. Here, CASZ1 is linked to clear cell renal carcinoma.